z-logo
open-access-imgOpen Access
Predicting Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer in Kenya: Utility of Ki67
Author(s) -
Edwin Obiri Mogere,
Joseph Githaiga,
Francis Owilla,
Mary Mungania,
Daniel Ojuka
Publication year - 2021
Publication title -
the annals of african surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.114
H-Index - 4
eISSN - 2523-0816
pISSN - 1999-9674
DOI - 10.4314/aas.v18i1.5
Subject(s) - medicine , breast cancer , chemotherapy , confidence interval , oncology , context (archaeology) , neoadjuvant therapy , cutoff , demographics , observational study , prospective cohort study , cancer , gynecology , demography , paleontology , physics , quantum mechanics , sociology , biology
Background: Ki67 levels have been shown to have good predictive value in breast cancer treatment. There is paucity of data on Ki67 levels in predicting response to neoadjuvant chemotherapy (NACT) in Kenya. This study evaluated the utility of Ki67 in predicting response to NACT. Methods: This was a prospective observational study carried out at Kenyatta National Hospital between December 2017 and January 2019 onpatients with locally advanced breast cancer. We recruited 61 women through consecutive sampling technique. Data collected included patient demographics, pre-treatment tumor size, Ki67 levels and tumor biology. After 3 cycles of first-line chemotherapy, ultrasonography was used to determine response. Data were analyzed by SPSS for proportion of change in tumor size. The response was correlated with tumor biology and pretreatment levels of Ki67 using chisquare at a 95% confidence interval. A p-value <0.05 was considered statistically significant. Results: The response rate after 3 cycles of NACT was 39.4%, sensitivity and specificity of Ki67 levels were 70.8% and 43.2% respectively with a cut-off value of 32.5%. Conclusions: Ki67 was found to predict response in our context at a rate of 39.4% at 20% cutoff after 3 cycles. Keywords: Ki67, Breast cancer, Neoadjuvant chemotherapy

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here